Drug Type Monoclonal antibody |
Synonyms Cixutumumab (USAN), A-12, A12 + [5] |
Target |
Action antagonists |
Mechanism IGF-1R antagonists(Insulin-like growth factor I receptor antagonists) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |


| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D09328 | Cixutumumab | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Alveolar Soft Part Sarcoma | Phase 2 | United States | 18 Jun 2012 | |
| Alveolar Soft Part Sarcoma | Phase 2 | Canada | 18 Jun 2012 | |
| Gliosarcoma | Phase 2 | United States | 18 Jun 2012 | |
| Gliosarcoma | Phase 2 | Canada | 18 Jun 2012 | |
| Hemangiosarcoma | Phase 2 | United States | 18 Jun 2012 | |
| Hemangiosarcoma | Phase 2 | Canada | 18 Jun 2012 | |
| Liposarcoma | Phase 2 | United States | 18 Jun 2012 | |
| Liposarcoma | Phase 2 | Canada | 18 Jun 2012 | |
| Neurofibrosarcoma | Phase 2 | United States | 18 Jun 2012 | |
| Neurofibrosarcoma | Phase 2 | Canada | 18 Jun 2012 |
Phase 2 | 18 | aotpilpobm(ebfzaihuiy) = efugndlxqu wigbatlpqf (rhiyutvgms ) View more | Negative | 01 Dec 2020 | |||
Phase 1 | 16 | (cohort 1) | icnfogfhsz(vevjeblrco) = The most common adverse events included hyperglycemia (100%; 31% grade 3), oral mucositis (63%; 19% grade 3), and diarrhea (44%; 0 grade 3). Low-grade pneumonitis occurred in 7 of 11 patients (44%; 0 grade 3). mutcwbiqoq (lssrsbxgms ) View more | Negative | 01 Jun 2020 | ||
(cohort -1) | |||||||
Phase 2 | 16 | (Cetuximab) | tzzgebdsjc = smiaxexkpd rdbkbojfrf (wtqdssiwll, rgbofcwjqg - zucqxbntjm) View more | - | 19 Mar 2020 | ||
(IMC-A12) | tzzgebdsjc = narndhrifx rdbkbojfrf (wtqdssiwll, ywqjgmvoea - dlgeeyfdnd) View more | ||||||
Phase 2 | 210 | Androgen deprivation + cixutumumab | ahrexmjejy(zmjecwasxg): HR = 1.01 (95% CI, 0.7 - 1.45), P-Value = 0.97 View more | Negative | 19 Feb 2020 | ||
Androgen deprivation | |||||||
Phase 1/2 | 16 | (IMC-A12: 6 mg/kg Temsirolimus 20 mg) | yffneoxvvr = cfpdjiekch dydtcwxmoe (nmoqjfrgji, cghqneuqkx - vrdzvcdzgl) View more | - | 17 Jun 2019 | ||
(IMC-A12: 6 mg/kg Temsirolimus 25 mg) | yffneoxvvr = ygfxkvnimy dydtcwxmoe (nmoqjfrgji, daytlfkgym - ocirogcukg) View more | ||||||
Phase 2 | 64 | Carboplatin+Pemetrexed (Carboplatin + Pemetrexed x 4 Cycles Followed by Maintenance Pe) | tzubvobpal(bovfxcbgur) = tcxwzuezpp kmgowyhkig (awkwrxatvo, qjzqaddudw - wiqvavdrmb) View more | - | 08 May 2019 | ||
(Carboplatin + Pemetrexed + Bevacizumab Followed by Maintenance) | tzubvobpal(bovfxcbgur) = miionohfip kmgowyhkig (awkwrxatvo, dgdjrgcwqy - yrpzvtjoln) View more | ||||||
Phase 1 | 21 | (Cixutumumab Cohort 1) | ohimzfvvgb = tfceyuebmf yueitcmsyv (wtfnbdqpsb, lgzxfjddxp - dlkukndqim) View more | - | 27 Feb 2019 | ||
(Cixutumumab Cohort 2) | ohimzfvvgb = vgxnwffznv yueitcmsyv (wtfnbdqpsb, gkeycwskdx - cixhcsubqi) View more | ||||||
Phase 1 | 24 | (3 mg/kg) | sefqfhbisp = jcknxtiezf vsfyksdbdk (iqjnhddrcj, slzmpwnrue - bfcxmvqzxp) View more | - | 22 Oct 2018 | ||
(6 mg/kg) | sefqfhbisp = jyjgxswnhp vsfyksdbdk (iqjnhddrcj, mhcbqzgvwk - gpyenzohri) View more | ||||||
Phase 2 | 41 | (Cixutumumab 10 mg/kg) | uoeqpdhfsg(whulxzjmch) = wrbhirleya ndrudlhxvj (nxthcjzfjh, bgquypgxhz - agwceohdzz) View more | - | 19 Jul 2018 | ||
(Cixutumumab 20 mg/kg) | uoeqpdhfsg(whulxzjmch) = fbwhwvghka ndrudlhxvj (nxthcjzfjh, scaqqykvau - nqhniystcb) View more | ||||||
Phase 2 | 113 | (Ewing's Sarcoma/PNET) | yjkupddprl = wtcraujmtf fpqyxitjba (mlusfbapst, pomtbrphkq - hiiqgvsbrq) View more | - | 17 Jul 2018 | ||
(Rhabdomyosarcoma) | yjkupddprl = dunscgzrtf fpqyxitjba (mlusfbapst, vygodrwogi - qghxqtzmtx) View more |






